You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
Title |
Fingolimod in active multiple sclerosis: an impressive decrease in Gd-enhancing lesions
|
---|---|
Published in |
BMC Neurology, August 2014
|
DOI | 10.1186/s12883-014-0164-5 |
Pubmed ID | |
Authors |
Anne-Hilde Muris, Linda Rolf, Jan Damoiseaux, Ellen Koeman, Raymond Hupperts |
Abstract |
Fingolimod is a disease modifying therapy (DMT) in highly active relapsing remitting multiple sclerosis (RRMS), as is natalizumab. Fingolimod decreases annual relapse rates and gadolinium enhancing lesions on MRI as compared to either interferon beta (IFNβ) or placebo. The effect of fingolimod on MRI outcomes compared to natalizumab treatment has not been investigated in (head to head) clinical trials. Clinical experience with natalizumab is much more extended and in general practice often preferred. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Egypt | 1 | 50% |
Unknown | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 47 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 2% |
Spain | 1 | 2% |
Brazil | 1 | 2% |
Unknown | 44 | 94% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 9 | 19% |
Student > Ph. D. Student | 7 | 15% |
Student > Bachelor | 7 | 15% |
Other | 3 | 6% |
Student > Doctoral Student | 2 | 4% |
Other | 7 | 15% |
Unknown | 12 | 26% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 19 | 40% |
Agricultural and Biological Sciences | 3 | 6% |
Biochemistry, Genetics and Molecular Biology | 2 | 4% |
Neuroscience | 2 | 4% |
Psychology | 2 | 4% |
Other | 4 | 9% |
Unknown | 15 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 August 2014.
All research outputs
#14,198,795
of 22,760,687 outputs
Outputs from BMC Neurology
#1,220
of 2,428 outputs
Outputs of similar age
#121,278
of 235,611 outputs
Outputs of similar age from BMC Neurology
#16
of 42 outputs
Altmetric has tracked 22,760,687 research outputs across all sources so far. This one is in the 35th percentile – i.e., 35% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,428 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.7. This one is in the 45th percentile – i.e., 45% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 235,611 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 42 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 59% of its contemporaries.